The FDA grants 510(k) clearance for Baxter International’s (NYSE:BAX) PrisMax system and integrated TherMax blood warmer, its next-generation platform for continuous renal replacement therapy and therapeutic plasma exchange.
PrisMax is commercially available in more than 20 countries across Europe and in Australia. Additional marketing applications will be filed through 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.